Nuvectis Pharma
NVCT
12 hedge funds and large institutions have $10M invested in Nuvectis Pharma in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 0 reducing their positions, and 1 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
40% more capital invested
Capital invested by funds: $7.2M → $10M (+$2.85M)
9% more funds holding
Funds holding: 11 → 12 (+1)
4.63% more ownership
Funds ownership: 5.06% → 9.68% (+4.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$5.9M |
| 2 |
RC
Ronit Capital
London,
United Kingdom
|
+$1.33M |
| 3 |
BWP
Baldwin Wealth Partners
Marion,
Massachusetts
|
+$112K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$69.6K |
| 5 |
BlackRock
New York
|
+$63.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$393K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $4.49M | +$5.9M | +632,979 | New |
|
|
RC
2
Ronit Capital
London,
United Kingdom
| $3.99M | +$1.33M | +143,265 | +34% |
|
|
BWP
3
Baldwin Wealth Partners
Marion,
Massachusetts
| $943K | +$112K | +12,000 | +10% |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $222K | +$69.6K | +7,474 | +31% |
|
5
Vanguard Group
Malvern,
Pennsylvania
| $192K | +$35.4K | +3,804 | +16% |
|
|
6
BlackRock
New York
| $100K | +$63.4K | +6,805 | +95% |
|
7
State Street
Boston,
Massachusetts
| $83K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $29K | +$25.8K | +2,773 | +217% |
|
9
UBS Group
Zurich,
Switzerland
| $2K | +$1.47K | +158 | +255% |
|
10
Morgan Stanley
New York
| $1K | +$9 | +1 | +0.5% |
|
11
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$708 | +76 | New |
|
|
12
Citadel Advisors
Miami,
Florida
| – | -$393K | -35,069 | Closed |
|
13
Wells Fargo
San Francisco,
California
| – | +$28 | +3 | +14% |
|
NVCT Hedge Fund Activity: Q3 2022 in Review
12 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q3 2022, worth a combined $10M — up 40% from $7.2M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new NVCT positions and 1 closed out — a net gain of 1 holder — while 9 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $5.9M. The largest seller was Citadel Advisors, exiting entirely with an estimated $393K sold.
- 12 institutional investors held Nuvectis Pharma (NVCT) as of Q3 2022, up from 11 in Q2 2022.
- Funds reported $10M of Nuvectis Pharma stock for Q3 2022, up 40% quarter-over-quarter.
- 2 funds opened new Nuvectis Pharma positions in Q3 2022 and 1 closed out, a net change of +1 holder.
- The largest Nuvectis Pharma buyer in Q3 2022 was Sabby Management, an estimated $5.9M added.
- The largest Nuvectis Pharma seller in Q3 2022 was Citadel Advisors, an estimated $393K sold.
Based on aggregated 13F filings for Q3 2022.